Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic drugs for treating serious autoimmune and kidney diseases. The company's flagship commercial product is Lupkynis (voclosporin), an immunosuppressive agent approved for the treatment of adult patients with active lupus nephritis. Its core operations encompass commercial biopharmaceutical distribution, clinical-stage drug development, and immunological research. Revenue is derived primarily from the global commercial sales of Lupkynis to healthcare providers and specialty pharmacies. Aurinia Pharmaceuticals holds a specialized position in nephrology therapeutics and autoimmune disease management. The company is headquartered in Victoria, British Columbia, Canada, with operational headquarters in Edmonton, and its common shares trade on the Nasdaq Global Select Market and the Toronto Stock Exchange.
7 of the funds FundTelligence covers report a position in Aurinia Pharmaceuticals.
- Legal name
- Aurinia Pharmaceuticals Inc
- Sector
- Health Care
- Country
- Canada
- Funds holding it
- 7
Funds holding Aurinia Pharmaceuticals
- Mercer Global Small Cap Equity Fund — Mercer · 0.26 % (full portfolio disclosed, December 2025)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.19 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.14 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Flerfaktor — KLP · 0.09 % (full portfolio disclosed, June 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)